Medical AI company Lunit said Thursday that it would present seven research studies using its AI biomarker platform, “Lunit SCOPE,” at the 2024 American Society of Clinical Oncology (ASCO 2024) in Chicago, U.S., from May 31 to June 4.

Lunit will present a poster on identifying HER2 Ultra-Low breast cancer patients using AI, predicting immune checkpoint inhibitor (ICI) treatment response in non-small cell lung cancer (NSCLC) patients based on pathology image and CT image data analysis.

In addition, the company will present a poster on:

-- Predicting recurrence risk and disease-free survival of hormone receptor-positive early breast cancer patients using AI

-- Analyzing immunophenotyping and immune checkpoint inhibitor response of melanoma patients in the East and West, focusing on differences between the East and West

-- AI-based tertiary lymphoid structure analysis for predicting immuno-oncology treatment response in NSCLC patients

-- Analyzing immune-chemo combination therapy vs. immuno-oncology monotherapy in NSCLC patients based on individual patient-level survival data reported in clinical trials.

"We continue to demonstrate the superior technology and clinical performance of Lunit SCOPE at world-renowned conferences such as ASCO," Lunit CEO Brandon Suh said. "We will continue to focus on R&D to make Lunit SCOPE the next essential biomarker platform for immuno-oncology treatment decisions and expand our product line to cover a broader range of cancers."

Founded in 1965, ASCO is recognized as one of the world's three leading cancer societies, along with the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO). It annually brings together more than 40,000 academics and industry representatives to share the latest research and industry trends.

Lunit has participated in ASCO every year since 2019, showcasing innovative research in AI biomarker technology.